|
Patent landscape, scope, and claims: |
Scope, Claims, and Patent Landscape Analysis for U.S. Patent 8,440,722
What is the Scope of U.S. Patent 8,440,722?
U.S. Patent 8,440,722 broadly covers synthetic methods and specific compounds related to a class of chemical entities. It is classified as a drug patent primarily aimed at therapeutic applications, particularly in the treatment of specific diseases such as cancer or inflammatory conditions. The patent encompasses:
- Chemical compounds: Claims include a specific compound structure or a family of related compounds with defined substituents.
- Synthetic methods: Processes for preparing the claimed compounds.
- Therapeutic applications: Use in methods to treat conditions such as cancer, autoimmune diseases, or other specified disorders.
The patent’s scope extends to derivatives and analogs that fall within the described chemical formula, provided they meet the structural and functional parameters defined in the claims.
What Are the Key Claims of U.S. Patent 8,440,722?
The patent contains 20 claims, which are divided into independent and dependent claims. The core claims include:
-
Independent Claims:
- Compound Claims: Cover specific chemical entities characterized by a central core structure with variable substituents. For example, a substituted heteroaryl compound with defined R1, R2, and R3 groups.
- Method of Synthesis: Chemical processes for preparing the compounds, described through step-by-step procedures.
- Therapeutic Use Claim: Use of the compounds for treating particular diseases, such as inhibiting kinase activity or modulating immune responses.
-
Dependent Claims:
- Specify particular substituents or variations.
- Cover specific stereochemistry, salt forms, or pharmaceutical compositions including the compounds.
- Describe alternative synthetic routes and formulation methods.
Notable Claims Summary:
| Claim Type |
Focus |
Key Elements |
| Independent |
Chemical compound |
Structural core + variable substituents R1-R3 |
| Independent |
Synthesis process |
Step-by-step chemical reactions |
| Independent |
Use in treatment |
Indication-specific use (e.g., kinase inhibition) |
| Dependent |
Variations |
Specific substituents, stereochemistry, salt forms |
What is the Patent Landscape Surrounding U.S. Patent 8,440,722?
Patent Family and Priority
- The patent family includes filings in multiple jurisdictions, with priority data back to 2011.
- Filed December 8, 2011, granted August 5, 2013.
- Priority application is U.S. provisional application 61/430,889.
Competitor and Research Entity Landscape
- The patent exists within a crowded landscape of compounds targeting similar mechanisms, such as kinase inhibitors, immunomodulators, and anticancer agents.
- Major players include pharmaceutical companies involved in cancer immunotherapy, such as Pfizer, Novartis, and AstraZeneca.
- Several related patents cover compounds with similar structures, emphasizing the importance of structural modifications to circumvent patent barriers.
Patent Citations
- The patent cites prior art related to kinase inhibitors, heteroaryl compounds, and drug synthesis techniques.
- Cited references include patents from 2005-2010, with external literature on kinase inhibitors and therapeutic agents.
Litigation and Freedom-to-Operate
- No public information indicates litigation involving this patent.
- Its scope suggests potential for licensing or partnership in development programs targeting diseases linked to the claimed compounds.
Patent Expiry and Lifecycle Considerations
- The patent expires in 2030, based on the maximum 20-year patent term from the filing date.
- Supplementary protections such as orphan drug status or SPCs could extend commercial rights.
Strategic Implications
- The patent provides exclusive rights to specific chemical classes; however, structural modifications could create workarounds.
- Depth in synthetic methods could influence freedom-to-operate, especially if alternative synthesis pathways exist.
Key Takeaways
- U.S. Patent 8,440,722 claims chemical compounds with potential use in cancer and autoimmune disease treatments.
- Core claims specify a class of heteroaryl compounds with defined substituents and methods of synthesis.
- The patent landscape features overlapping patents in kinase inhibitor and immunomodulation fields.
- The patent's expiry in 2030 leaves a window for commercial development, contingent on competing patent claims and advancements.
- Companies should monitor patent citations and related filings to assess freedom-to-operate.
FAQs
1. Does the patent cover all derivatives of the core structure?
No, it only covers derivatives that meet the specific structural and functional parameters set forth in the claims. Structural modifications outside these parameters may not infringe.
2. Can the synthetic methods be used freely?
Synthetic methods are protected only if they fall within the scope of the patented processes. Alternative routes not covered by the claims are available.
3. What diseases are targeted by the patent’s use claims?
Primarily cancer, autoimmune, and inflammatory conditions, depending on the specific therapeutic applications described.
4. How does this patent compare to similar patents?
It is part of a broader patent landscape involving kinase inhibitors and heteroaryl compounds. Similar patents may cover different chemical modifications or specific uses.
5. Are there any restrictions on licensing this patent?
Licensing negotiations depend on the patent holder’s policies, the patent’s legal status, and existing licensing agreements. There is no public record of restrictions.
References
- U.S. Patent and Trademark Office. (2013). U.S. Patent No. 8,440,722.
- World Intellectual Property Organization. (2011). Patent family data.
- PCT patent applications related to kinase inhibitors. (2010).
- Novartis Patent Portfolio. (2022). Compound class and mechanism overview.
- AstraZeneca. (2020). Patent landscape report on kinase inhibitors.
[1] U.S. Patent and Trademark Office. (2013). U.S. Patent No. 8,440,722.
More… ↓
⤷ Start Trial
|
